Finding value in the U.S. Food and Drug Administration's Fast Track program.
The U.S. Food and Drug Administration's (FDA) Fast Track program, created in 1997, was designed to facilitate the development and expedite the review of drugs and biologics intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. Although the intent is laudable, the significance of designations and effectiveness of the program have recently come into question. Tufts Center for the Study of Drug Development has collected data on fast track candidates since 1998. We analyzed the current dataset of 344 fast track candidates granted nearly 400 designations, representing approximately 70% of the fast track designations granted by FDA, to address questions regarding common metrics. We found that fast track candidates were widely diverse in characteristics and development histories. The complexity and limitations of the data introduced biases in metrics such as clinical phase lengths and phase transition probabilities, although these could be determined for subsets of the candidates. Our results suggest that evaluation of the Fast Track program requires a nuanced approach, and estimates of the program's value should include assessment of the resulting marketed products.
Reichert
Janice M
JM
Tufts Center for the Study of Drug Development, Boston, Massachusetts 02111, USA. janice.reichert@tufts.edu
Rochon
Stephanie L
SL
Zhang
Bodi D
BD
D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence* / Q000379:methods; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000592:standards; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational